Xspray Pharma publ AB

Xspray Pharma operates with a capital structure that includes total assets of SEK 736.1 million and total liabilities of SEK 67.9 million, resulting in a debt-to-equity ratio of 0.05. The company's liquidity position is characterized by a current ratio of 4.67, indicating a strong ability to meet short-term obligations. However, the company reported negative operating cash flow of SEK -119.5 million and free cash flow of SEK -59.97 million, suggesting significant cash outflows from operations.

Profitability metrics for Xspray Pharma are negative, with a return on equity (ROE) of -8.02% and a return on assets (ROA) of -7.28%. These figures are below the industry median for ROE and ROA, which are typically positive for companies in the biotechnology and medical research sector. The company's net income was SEK -53.58 million, and operating income was SEK -54.07 million, reflecting ongoing losses.

The company's revenue is currently reported at SEK 0.00, indicating no revenue generation in the latest period. There is no disclosed segment or geographic breakdown of revenue, as the company has not provided such information in its latest financial statements. This lack of transparency makes it difficult to assess the company's exposure to different markets or product lines.

Looking ahead, the company's growth trajectory is uncertain. Analysts have estimated a mean revenue of SEK 695.5 million for the upcoming period, but the company's current revenue is SEK 0.00. The mean EPS estimate is SEK 2.75, while the last actual EPS was SEK -4.34, indicating a significant gap between expectations and performance. The company's capital expenditures were SEK -13.89 million, suggesting ongoing investment in infrastructure or R&D.

The company faces several risk factors, including liquidity risk due to negative operating and free cash flows. The risk assessment indicates a medium liquidity risk, with key flags pointing to negative net cash after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance. However, the company's ongoing losses and lack of revenue raise concerns about its long-term viability.

Recent events and disclosures include analyst estimates that are uniformly set at SEK 58.35 for the price target, with a mean EPS estimate of SEK 2.75. The last actual EPS was SEK -4.34, highlighting the discrepancy between analyst expectations and the company's current performance. The company has not disclosed any recent filings or transcripts that provide additional insight into its operations or strategic direction.

Analysts project 282% upside to a mean price target of 58.35 SEK, significantly above the current market price of 15.26 SEK.

Cash conversion metrics rank best-in-class at 2.23, substantially exceeding the cohort median of 0.87 for biotechnology peers.

Operating losses improved by 45.3% year-over-year in FY2026, narrowing to -156.9 million SEK from -287.0 million SEK in FY2025.

Free cash flow burn decreased by 38.8% year-over-year to -195.0 million SEK in FY2026, suggesting improved cash management efficiency.

The company carries a high credit risk flag, signaling potential difficulties in meeting financial obligations or securing favorable financing terms.

Revenue remains at zero SEK across all reported fiscal years from 2022 to 2026, indicating a complete lack of commercial product sales.

Long-term debt surged to 128.2 million SEK in FY2025, a significant increase from just 3.2 million SEK in FY2022.

The company faces medium liquidity risk, which may constrain its ability to fund ongoing operations and development activities.

Net losses widened to -285.5 million SEK in FY2025, reflecting a substantial deterioration in profitability compared to previous years.

Revenue kr 0.00; Operating income -kr 81.9M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 81.9M

Revenue kr 0.00; Operating income -kr 82.7M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 82.7M

Revenue kr 0.00; Operating income -kr 54.1M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 54.1M

Revenue kr 0.00; Operating income +45,3% YoY.

• ▍Revenue kr 0.00
• ▍Operating income +45,3% YoY
• ▍Net income +40,0% YoY
• ▍Free cash flow +38,8% YoY

Revenue kr 0.00; Operating income −58,0% YoY.

• ▍Revenue kr 0.00
• ▍Operating income −58,0% YoY
• ▍Net income −58,9% YoY
• ▍Free cash flow −47,5% YoY

Revenue kr 0.00; Operating income −36,6% YoY.

• ▍Revenue kr 0.00
• ▍Operating income −36,6% YoY
• ▍Net income −36,5% YoY
• ▍Free cash flow +13,7% YoY

Revenue kr 0.00; Operating income −35,9% YoY.

• ▍Revenue kr 0.00
• ▍Operating income −35,9% YoY
• ▍Net income −36,2% YoY
• ▍Free cash flow −36,1% YoY

Revenue kr 0.00; Operating income -kr 98.0M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 98.0M